UARK, 98-032, Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
Patients will take Thalidomide tablets at bedtime daily until remission. The dose will be
increased gradually and modified according to side-effects. The drug will be given daily up
to the time of complete remission then as long as it is beneficial.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the efficacy and safety of Thalidomide in patients with leukemia.
Barthel Barlogie, M.D., Ph.D.
United States: Food and Drug Administration
|University of Arkansas for Medical Sciences/MIRT||Little Rock, Arkansas 72205|